Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (820)	9/16/1998 7:32:00 PM
From: Anthony Wong	Respond to of 1722

George, it's a well-written article. I don't own AHP or Immunex, but congratulations to those who do.

To: aknahow who wrote (820)	9/16/1998 7:38:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 1722

American Home's Enbrel Could Earn $500 Mln a Year, NYT Reports Bloomberg News September 16, 1998, 10:05 a.m. ET Madison, New Jersey, Sept. 16 (Bloomberg) -- American Home Products Corp. is expected to receive Food and Drug Administration approval within weeks to market Enbrel, its new injectable rheumatoid arthritis drug, and analysts project worldwide sales at over $500 million a year, the New York Times reported in its ''Market Place'' column. Next year, American Home plans to begin selling a new gastrointestinal drug, Protonix, and an immuno-suppression therapy for organ transplants, Rapamune, with analysts predicting sales for each to top $1 billion a year. American Home, which recalled its painkiller Duract this year, could face more troubles, including lawsuits from the ''fen- phen'' diet drug and possible Federal Trade Commission objections to its pending acquisition of Monsanto Co., the paper said. Last week, American Home quietly settled at least two lawsuits filed by women who claimed that the ''fen-phen'' diet- drug combination caused their pulmonary hypertension, a rare and often fatal lung condition. (NYT 9/16 C7 www.nytimes.com) --Mary Guidry in the Princeton newsroom (609) 279-4028 /jjs